IMMUNOLOGY TODAY

Copyright statement

© 1999 Elsevier Science Ltd. All rights reserved.
This journal and the individual contributions contained in it are protected under copyright by Elsevier Science Ltd, and the following terms and conditions apply to their use:

Photocopying
Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.
Permissions may be sought directly from Elsevier Science Global Rights Department, PO Box 800, Oxford, UK OX5 1DX; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.co.uk. You may also contact Global Rights directly through Elsevier's home page (http://www.elsevier.nl), selecting first 'Customer Support', then 'General Information', then 'Permissions Query Form'.
In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 (978) 750 8400, fax: +1 (978) 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London, UK W1P 0LP; phone: (+44) 171 631 5555, fax: (+44) 171 631 5500. Other countries may have a local reprographic rights agency for payments.

Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution.
Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic Storage or Usage
Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article.
Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.
Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above.

Notice
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Published by:
Elsevier Science London
84 Theobald's Road
London, UK WC1X 8RR.

Printed in the United Kingdom

IMMUNOLOGY TODAY

Advisory Editorial Board
J.D. Ashwell *Bethesda, USA*
F.H. Bach *Harvard, USA*
J.F. Bach *Paris, France*
T. Boon *Brussels, Belgium*
C.A. Janeway, Jr *New Haven, USA*
T. Kishimoto *Osaka, Japan*
D. Mathis *Strasbourg, France*
F. Melchers *Basel, Switzerland*
T. Mosmann *Edmonton, Canada*
G.J.V. Nossal *Melbourne, Australia*
A. Rao *Boston, USA*
K.B.M. Reid *Oxford, UK*
E. Simpson *Harrow, UK*
R. Zinkernagel *Zürich, Switzerland*

Editors
Elaine Bell and Rob Brines

Assistant Editor
Kirsty McCormack

Editorial Administrators
Liam Benison, Alan Sloan, Helen Steele and Anne Ward

Publishing Manager
Rob Brines

REFERENCE EDITION
Volume 20
1999

ELSEVIER
SCIENCE
LONDON

IMMUNOLOGY TODAY – REFERENCE EDITION

Published by Elsevier Trends Journals

The reference edition of *Immunology Today* is a compilation of the regular monthly magazine edition. For citation purposes, the page numbers of reprinted articles are common to both editions.

Aims and Scope

The aim of *Immunology Today* is to monitor advances in the various fields of immunology and bring together the results in a readable and lucid form. Review articles form the backbone of each monthly issue, complemented by Viewpoint articles that are a forum for discussion of more speculative topics or new hypotheses. Review and Viewpoint articles, together with other sections of the journal (Update, Trends, Letters and Book Reviews), ensure that *Immunology Today* provides readers with a broad picture of the diverse field of immunology.

Editorial Policy

Articles in *Immunology Today* are usually commissioned by the Editor. Prospective authors who wish to write should approach the Editor with a brief outline of their proposed article. The Editor will decide whether to commission the article, and will issue instructions for manuscript preparation. Authors should note that manuscripts may be rejected as a result of the peer and editorial review process: commissioning does not guarantee publication.

Editor

Elaine Bell PhD, Elsevier Science London, 84 Theobald's Road, London, UK WC1X 8RR.
Tel: +44 (0)20 7611 4400, Fax: +44 (0)20 7611 4470, e-mail: it@current-trends.com, http://www.trends.com

Immunology Today is apolitical. The views and opinions expressed by its writers and correspondents do not necessarily reflect those of the Editorial Staff, the Editorial Board or the Publisher.

IMMUNOLOGY TODAY REFERENCE EDITION

Volume 20 1999

CONTENTS

January

UPDATE

Current literature 1

TRENDS

Complement genetics: biological implications of polymorphisms and deficiencies *P.M. Schneider and R. Würzner* 2

New perspectives on immunobiology and immunotherapy of melanoma *F.O. Nestle, G. Burg and R. Dummer* 5

On the intrathymic intercellular transfer of self-determinants *C. Viret, A.K. Barlow and C.A. Janeway, Jr* 8

Genetic risk factors for autoimmune diseases *T.E.W. Feltkamp, L.A. Aarden, C.J. Lucas, C.L. Verweij and R.R.P. de Vries* 10

VIEWPOINT

Transcriptional enhancers and the evolution of the IgH locus *B.G. Magor, D.A. Ross, L. Pilström and G.W. Warr* 13

Does properdin crosslink the cellular and the humoral immune response? *W.J. Schwaeble and K.B.M. Reid* 17

A new taxonomy of mammalian MHC class I molecules *A.L. Hughes, M. Yeager, A.E. Ten Elshof and M.J. Chorney* 22

Are dendritic cells the key to liver transplant tolerance? *A.W. Thomson and L. Lu* 27

A kinetic differentiation model for the action of altered TCR ligands *G.M. Lord, R.I. Lechler and A.J.T. George* 33

REVIEW

The pathogenesis of psoriasis: immunological facts and speculations *J.D. Bos and M.A. De Rie* 40

The Fas counterattack: cancer as a site of immune privilege *J. O'Connell, M.W. Bennett, G.C. O'Sullivan, J.K. Collins and F. Shanahan* 46

COMMENT

Letters 53

Book Reviews 55

February

TRENDS

Cytokine pleiotropy and redundancy – gp130 cytokines in human implantation *J. Sanchéz-Cuenca, J.C. Martín, A. Pellicer and C. Simón* 57

HLA-G: a tolerance molecule from the major histocompatibility complex *E.D. Carosella, N. Rouas-Freiss, P. Paul and J. Dausset* 60

Advances in cancer immunotherapy *D. Ockert, M. Schmitz, M. Hampl and E.P. Rieber* 63

VIEWPOINT

Alloimmunization for immune-based therapy and vaccine design against HIV / AIDS *G.M. Shearer, L.A. Pinto and M. Clerici* 66

Multiple gc-dependent cytokines regulate T-cell development *T.R. Malek, B.O. Porter and Y-W. He* 71

Direct and indirect recognition: the role of MHC antigensin graft rejection *D.S. Gould and H. Auchinloss, Jr* 77

REVIEW

CD13 – not just a marker in leukemia typing *D. Riemann, A. Kehlen and J. Langner* 83

Chemokine receptors and HIV-1: the fusion of two major research fields *R. Horuk* 89

Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic *N.A. Williams, T.R. Hirst and T.O. Nashar* 95

COMMENT

Letters 102

Book Reviews 104

March

UPDATE

Current literature 107

TRENDS

Cow's milk and type I diabetes: the gut immune system deserves attention *H. Kolb and P. Pozzilli* 108

Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation *J.A. Denburg* 111

VIEWPOINT

An innate view of human pregnancy *G. Sacks, I. Sargent and C. Redman* 114

Immune cell signaling defects in lupus: activation, anergy and death *G.C. Tsokos and S-N.C. Liossis* 119

Phosphorylcholine: friend or foe of the immune system? *W. Harnett and M.M. Harnett* 125

Tissue transglutaminase: apoptosis versus autoimmunity *M. Piacentini and V. Colizzi* 130

REVIEW

FHL-1 reconectin: a human complement and immune regulator with cell-adhesive function *P.F. Zipfel and C. Skerka* 135

Regional specialization in the mucosal immune system: what happens in the microcompartments? *P. Brandtzaeg, E.S. Baekkevold, I.N. Farstad, F.L. Jahnsen, F-E. Johansen, E.M. Nilsen and T. Yamanaka* 141

COMMENT

Letters 152

April

UPDATE

Current literature 155

TRENDS

Turning the immune system on *J. Borst and A. Cope* 156

Where have all the T cells gone? Mechanisms of immune evasion by tumors *J. Finke, S. Ferrone, A. Frey, A. Mufson and A. Ochoa* 158

MHC-based diagnostics and therapeutics – clinical applications for disease-linked genes *M.C. Howard, E.G. Spack, K. Choudhury, T.F. Greten and J.P. Schneck* 161

Major histocompatibility complex: from genes to function *D.J. Moss and R. Khanna* 165

Research directions in paroxysmal nocturnal hemoglobinuria *D.E. Dunn, R.E. Ware, C.J. Parker, H.O. Mishoe and N.S. Young* 168

VIEWPOINT

Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation? *J.L. Cohen, O. Boyer and D. Klatzmann* 172

Faces and phases of human CD81 T-cell development *D. Hamann, M.Th.L. Roos and R.A.W. van Lier* 177

Immunotherapy with CTLs restricted by nonself MHC *H.J. Stauss* 180

REVIEW

The key role of PU.1/SPI-1 in B cells, myeloid cells and macrophages *J. Lloberas, C. Soler and A. Celada* 184

Antigen-based immunotherapy for autoimmune disease: from animal models to humans? *J. Tian, A. Olcott, L. Hanssen, D. Zekzer and D.L. Kaufman* 190

COMMENT

Letters 196

Book Review 198

May

UPDATE

Online access to *Immunology Today* 199

TRENDS

Coordinated events during bacteria-induced DC maturation *M. Rescigno, F. Granucci, S. Citterio, M. Foti and P. Ricciardi-Castagnoli* 200

The influence of antiviral T-cell responses on the alloreactive repertoire *S.R. Burrows, R. Khanna, S.L. Silins and D.J. Moss* 203

The evolution, structure, biology and pathophysiology of complement *J.D. Lambris, K.B.M. Reid and J.E. Volanakis* 207

VIEWPOINT

Cytotoxic T lymphocytes, chemokines and antiviral immunity *D.A. Price, P. Klenerman, B.L. Booth, R.E. Phillips and A.K. Sewell* 212

Growing up on the streets: why B-cell development differs from T-cell development *S.E. Townsend, B.C. Weintraub and C.C. Goodnow* 217

The dynamics of HTLV-I and the CTL response *D. Wodarz, M.A. Nowak and C.R.M. Bangham* 220

Is T-cell priming required for initiation of pathology in malaria infections? *E.M. Riley* 228

REVIEW

Analysis of B-cell epitopes of the Ro/SS-A autoantigen *M. Wahren-Herlenius, S. Muller and D. Isenberg* 234

How LFA-1 binds to different ligands *M.E. Binnerts and Y. van Kooyk* 240

COMMENT

Letter 246

June

TRENDS

Immune correlates of protection from HIV and AIDS – more answers but yet more questions *J.L Heeney, P. Beverley, A. McMichael, G. Shearer, J. Strominger, B. Wahren, J. Weber and F. Gotch* 247

Delivery of DNA vaccines by attenuated intracellular bacteria *G. Dietrich, I. Gentschev, J. Hess, J.B. Ulmer, S.H.E. Kaufmann and W. Goebel* 251

VIEWPOINT

The chemokine system: redundancy for robust outputs *A. Mantovani* 254

Novel mechanism for the impairment of cell proliferation in HIV-1 infection *M. Bofill, N.J. Borthwick and H.A. Simmonds* 258

T-cell clonality in immune responses *M.K. Maini, G. Casorati, P. Dellabona, A. Wack and P.C.L. Beverley* 262

REVIEW

Regional specialization in the mucosal immune system: primed cells do not always home along the same track *P. Brandtzaeg, I.N. Farstad and G. Haraldsen* 267

ADAM family proteins in the immune system *S. Yamamoto, Y. Higuchi, K. Yoshiyama, E. Shimizu, M. Kataoka, N. Hijiya and K. Matsuura* 278

Structure and evolution of the extended B7 family *J. Henry, M.M. Miller and P. Pontarotti* 285

COMMENT

Letters 289

July

TRENDS

The generation and maintenance of memory T and B cells *R.W. Dutton, S.L. Swain and L.M. Bradley* 291

Hunting down the seminal cells of clinical metastases *G. Riethmüller, C.A. Klein and K. Pantel* 294

Autoantibodies revealed: the role of B cells in autoimmune disease *F.K. Stevenson and J. Natvig* 296

The neuroendocrine immune basis of rheumatic diseases *J.W.J. Bijlsma, M. Cutolo, A.T. Masi and I.C. Chikanza* 298

VIEWPOINT

Distribution of activated T cells migrating through the body: a matter of life and death *J. Westermann and U. Bode* 302

Cytokine/chemokine cascades in immunity to tuberculosis *I.M. Orme and A.M. Cooper* 307

CD5 expression in human B-cell populations *P. Youinou, C. Jamin and P.M. Lydyard* 312

Atopic disorders: a default pathway in the absence of infection? *K.J. Erb* 317

REVIEW

Efficacy of adhesive interactions in pig-to-human xenotransplantation *A.R. Simon, A.N. Warrens and M. Sykes* 323

T-cell function in newborn mice and humans *B. Adkins* 330

COMMENT

Letters 336

August

TRENDS

Anti-DNA autoantibodies: a puzzle of autoimmune phenomena *D. Eilat and Y. Naparstek* 339

Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients *Y. Reisner and M.F. Martelli* 343

Specific and nonspecific immunity in the prevention of spontaneous tumours *P-L. Lollini and G. Forni* 347

VIEWPOINT

CTL granules: evolution of vesicles essential for combating virus infections *J.A. Trapani, V.R. Sutton and M.J. Smyth* 351

GPI-microdomains: a role in signalling via immunoreceptors *V. Hořejší, K. Drbal, M. Cebecauer, J. Cerný, T. Brdička, P. Angelisová and H. Stockinger* 356

Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism *C.R. Alving and N.M. Wassef* 362

REVIEW

CD26, let it cut or cut it down *I. De Meester, S. Korom, J. Van Damme and S. Scharpé* 367

The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction *M.L. Lupher, Jr, N. Rao, M.J. Eck and H. Band* 375

COMMENT

Letters 383

Book Review 385

September

TRENDS

Immunity and probiotics *B. Dugas, A. Mercenier, I. Lenoir-Wijnkoop, C. Arnaud, N. Dugas and E. Postaire* 387

Granulysin: a lethal weapon of cytolytic T cells *S. Stenger, J-P. Rosat, B.R. Bloom, A.M. Krensky and R.L. Modlin* 390

Prometheus through the looking glass *C. O'Farrelly and I.N. Crispe* 394

Allergy to lipocalins: a consequence of misguided T-cell recognition of self and nonself? *T. Virtanen, T. Zeiler, J. Rautiainen and R. Mäntyjärvi* 398

VIEWPOINT

Cruel antibody fictions! Cellular antigen enumeration by saturation binding *R.P. Junghans* 401

Positive and negative regulation of Src-family membrane kinases by CD45 *M.L. Thomas and E.J. Brown* 406

CD45 and Src-family kinases: and now for something completely different *J.D. Ashwell and U. D'Oro* 412

REVIEW

Binding energetics of T-cell receptors: correlation with immunological consequences *T.C. Manning and D.M. Kranz* 417

Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity *G. Dighiero and N.R. Rose* 423

COMMENT

Letter 429

October

TRENDS

Integration of receptor-mediated signals in T cells by transmembrane adaptor proteins *B. Schraven, A. Marie-Cardine, C. Hübener, E. Bruyns and I. Ding* 431

Accommodation *M.P. Soares, Y. Lin, K. Sato, K.M. Stuhlmeier and F.H. Bach* 434

Measurement of T-cell kinetics: recent methodologic advances *M.K. Hellerstein* 438

VIEWPOINT

Regulatory T cells and inflammatory bowel disease *H. Groux and F. Powrie* 442

The moving target: mechanisms of HIV persistence during primary infection *H. Soudeyns and G. Pantaleo* 446

Pathogenic light chains and the B-cell repertoire *F.J. Stevens and Y. Argon* 451

Cancer immunotherapy: synthetic and natural peptides in the balance *M. Bellone, G. Iezzi, M.A. Imro and M.P. Protti* 457

REVIEW

Positive selection of thymocytes: the long and winding road *G. Anderson, K.J. Hare and E.J. Jenkinson* 463

Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? *A.L. Mellor and D.H. Munn* 469

COMMENT

Letters 474

November

TRENDS

Is there a balance between microglia and astrocytes in regulating Th1 / Th2-cell responses and neuropathologies? *B-G. Xiao and H. Link* 477

Tumour immunotherapy: developments and strategies *U. Chattopadhyay* 480

Immunology of ocular tumours *M. Zierhut, J.W. Streilein, H. Schreiber, M.J. Jager, D. Ruiter and B.R. Ksander* 482

Can eradication of helminthic infections change the face of AIDS and tuberculosis? *Z. Bentwich, A. Kalinkovich, Z. Weisman, G. Borkow, N. Beyers and A.D. Beyers* 485

VIEWPOINT

What is the real role of CD40 in cancer immunotherapy? *R.T. Costello, J-A. Gastaut and D. Olive* 488

Structure and mucosal adjuvanticity of cholera and *Escherichia coli* heat-labile enterotoxins *R. Rappuoli, M. Pizza, G. Douce and G. Dougan* 493

Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions *J.C. Gutierrez-Ramos, C. Lloyd and J.A. Gonzalo* 500

T cells orchestrate intestinal mucosal shape and integrity *T.T. MacDonald, M. Bajaj-Elliott and S.L.F. Pender* 505

Is rapeseed really an allergenic plant? Popular myths versus scientific realities *D.J. Murphy* 511

REVIEW

Conserved lipid and peptide presentation functions of nonclassical class I molecules *M. Kronenberg, L. Brossay, Z. Kurepa and J. Forman* 515

Mismatch repair and immunoglobulin gene hypermutation: did we learn something? *C-A. Reynaud, B. Bertocci, S. Frey, F. Delbos, L. Quint and J-C. Weill* 522

The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences *M. Humbert, G. Menz, S. Ying, C.J. Corrigan, D.S. Robinson, S.R. Durham and A.B. Kay* 528

COMMENT

Letter 534

December

TRENDS

Novel trends in neutrophil structure, function and development *F. Mollinedo, N. Borregaard and L.A. Boxer* 535

Thalidomide as an emerging immunotherapeutic agent *J.B. Marriott, G. Muller and A.G. Dalgleish* 538

Serpins: an evolutionarily conserved survival strategy *M. Salzet, D. Vieau and G.B. Stefano* 541

VIEWPOINT

The α_4-integrin: an alternative pathway for neutrophil recruitment? *B. Johnston and P. Kubes* 545

Immune (dys)regulation in multiple sclerosis: role of the CD95–CD95 ligand system *F. Zipp, P.H. Krammer and M. Weller* 550

Vaccination by inducing oral tolerance? *S.J. McSorley and P. Garside* 555

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal *P. Kaliński, C.M.U. Hilkens, E.A. Wierenga and M.L. Kapsenberg* 561

REVIEW

The role of T-cell receptor dimerization in T-cell activation *M.F. Bachmann and P.S. Ohashi* 568

Immune evasion of tumor cells using membrane-bound complement regulatory proteins *A. Gorter and S. Meri* 576

The contribution of ER quality control to the biologic functions of secretory IgM *P.S. Reddy and R.B. Corley* 582

COMMENT

Letter 588

Book Review 589

AUTHOR INDEX 591

SUBJECT INDEX 597

INDEX OF BOOKS REVIEWED 605